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BACKGROUND: T-wave inversion (TWI) is common in patients with 
cardiomyopathy. However, up to 25% of athletes of African/Afro-Caribbean 
descent (black athletes) and 5% of white athletes also have TWI of unclear 
clinical significance despite comprehensive clinical evaluation and long-term 
follow-up. The aim of this study was to determine the diagnostic yield from 
genetic testing, beyond clinical evaluation, when investigating athletes with TWI.
METHODS: We investigated 50 consecutive asymptomatic black and 50 white 
athletes 14 to 35 years of age with TWI and a normal echocardiogram who 
were referred to a UK tertiary center for cardiomyopathy and sports cardiology. 
Subjects underwent exercise testing, 24-hour ambulatory ECG, signal-averaged 
ECG, cardiac magnetic resonance imaging, and a blood-based analysis of a 
comprehensive 311-gene panel for cardiomyopathies and ion channel disorders 
associated with TWI, including hypertrophic cardiomyopathy, arrhythmogenic 
right ventricular cardiomyopathy, dilated cardiomyopathy, left ventricular 
noncompaction, long-QT syndrome, and Brugada syndrome.
RESULTS: In total, 21 athletes (21%) were diagnosed with cardiac disease on 
the basis of comprehensive clinical investigations. Of these, 8 (38.1%) were gene 
positive (myosin binding protein C [MYBPC3], myosin heavy chain 7 [MYH7], 
galactosidase alpha [GLA], and actin alpha, cardiac muscle 1 [ACTC1] genes) and 
13 (61.9%) were gene negative. Of the remaining 79 athletes (79%), 2 (2.5%) 
were gene positive (transthyretin [TTR] and sodium voltage-gated channel alpha 
subunit 5 [SCN5A] genes) in the absence of a clinical phenotype. The prevalence 
of newly diagnosed cardiomyopathy was higher in white athletes compared 
with black athletes (30.0% versus 12%; P=0.027). Hypertrophic cardiomyopathy 
accounted for 90.5% of all clinical diagnoses. All black athletes and 93.3% of 
white athletes with a clinical diagnosis of cardiomyopathy or a genetic mutation 
capable of causing cardiomyopathy exhibited lateral TWI as opposed to isolated 
anterior or inferior TWI; the genetic yield of diagnoses from lateral TWI was 
12.3%.
CONCLUSIONS: Up to 10% of athletes with TWI revealed mutations capable 
of causing cardiac disease. Despite the substantial cost, the positive diagnostic 
yield from genetic testing was one half that from clinical evaluation (10% versus 
21%) and contributed to additional diagnoses in only 2.5% of athletes with TWI 
in the absence of a clear clinical phenotype, making it of negligible use in routine 
clinical practice.
© 2018 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of 
the Creative Commons Attribution 
Non-Commercial-NoDerivs License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited, 
the use is noncommercial, and no 
modifications or adaptations are made.
Nabeel Sheikh, PhD
Michael Papadakis, MD
Mathew Wilson, PhD
Aneil Malhotra, PhD
Carmen Adamuz, MD
Tessa Homfray, MB BS
Lorenzo Monserrat, PhD
Elijah R. Behr, MD
Sanjay Sharma, MD
ORIGINAL RESEARCH ARTICLE
Diagnostic Yield of Genetic Testing in 
Young Athletes With T-Wave Inversion
https://www.ahajournals.org/journal/circ
Circulation
April292018
D
ow
nloaded from
 http://ahajournals.org by on October 8, 2018
Sheikh et al Gene Testing Athletes With T-Wave Inversion
Circulation. 2018;138:1184–1194. DOI: 10.1161/CIRCULATIONAHA.118.034208 September 18, 2018 1185
ORIGINAL RESEARCH 
ARTICLE
A small proportion of apparently healthy adult athletes exhibit marked repolarization abnor-malities in the absence of detectable structural 
heart disease. Of these repolarization patterns, most in-
terest has focused on T-wave inversion (TWI),1–9 which 
is a common manifestation of several inherited cardio-
myopathies and some ion channel diseases implicated 
in sudden cardiac death.
Although rare in adult white athletes,10–14 TWI is 
observed in up to one quarter of athletes of African/
Afro-Caribbean descent (black athletes) and most 
commonly confined to the anterior leads (V1–V4).
3,5 
Observational data suggest that this specific repo-
larization pattern represents a benign, ethnic mani-
festation of the athlete’s heart.3,5,15 In contrast, the 
clinical significance of inferior and lateral TWI is less 
certain. Recent studies using cardiac magnetic reso-
nance imaging (CMR)4 and longitudinal follow-up1,3,6 
in athletes with inferior or lateral TWI have reported 
an association with these repolarization changes and 
cardiomyopathy, risk of sudden cardiac arrest, or the 
subsequent development of cardiomyopathy over 
time. The majority of athletes in these studies, how-
ever, failed to reveal any demonstrable cardiac pa-
thology. None of these studies incorporated genetic 
testing to help determine whether TWI represented 
an early, subtle, or concealed manifestation of cardio-
myopathy or ion channel disease. Genetic testing was 
previously expensive and impractical, but next-gener-
ation sequencing16 has now offered major advances 
in the molecular genetics of inherited cardiac diseases 
and the development of relatively inexpensive genetic 
panels to investigate a broad spectrum of recognized 
mutations in genes implicated in cardiomyopathy and 
ion channel disorders.
The aim of this study was to examine the additional 
diagnostic yield for these genetic diseases beyond stan-
dard comprehensive clinical evaluation in highly trained 
black and white athletes with TWI using a wide genetic 
panel.
METHODS
Setting
The charitable organization Cardiac Risk in the Young (CRY) 
provides a national preparticipation screening service for 
several elite national sporting bodies and regional teams, 
including Aviva Premiership Rugby, British Rowing, English 
cricket, English Institute of Sport, Lawn Tennis Association, 
Rugby Football Union, and several Premiership soccer clubs. 
Athletes with abnormal findings undergo further investiga-
tions, of which >80% are conducted in the Sports Cardiology 
Unit at St. George’s Hospital. The principal investigator (S.S.) 
also receives referrals directly to the sports cardiology unit 
from other elite professional sporting bodies and other medi-
cal institutions throughout the United Kingdom. Since 2010, 
we have also received referrals from Qatar Orthopedic and 
Sports Medicine Hospital (Doha, Qatar), which has a highly 
active cardiovascular screening program that serves the entire 
Persian Gulf region. All elite athletes receive a 12-lead ECG 
and 2-dimensional echocardiography as part of these screen-
ing programs. 
The data, analytical methods, and study materials will not 
be made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Design and Recruitment of 
Athletes
Between April 2012 and April 2014, a total of 2039 athletes 
(260 black and 1779 white) were evaluated. Fifty consecu-
tive black and 50 consecutive white athletes 14 to 35 years 
of age with TWI ≥−0.1 mV in ≥2 contiguous leads (excluding 
aVR, V1, and lead III in isolation) were prospectively recruited 
into the study. Twenty-seven athletes were recruited through 
preparticipation cardiac evaluation performed by CRY in 
the United Kingdom and 14 through preparticipation car-
diac evaluation performed by Qatar Orthopedic and Sports 
Medicine Hospital in Doha. The remainder (n=59) were 
Clinical Perspective
What Is New?
• The yield of testing for pathogenic disease-causing 
genetic mutations in athletes exhibiting T-wave 
inversion is low (10%), despite the use of a com-
prehensive genetic panel.
• Gene testing in selected athletes referred to a ter-
tiary referral center contributes to additional diag-
noses beyond comprehensive clinical evaluation in 
only 2.5% of athletes with T-wave inversion with-
out a clear clinical phenotype.
• The overall diagnostic yield from genetic testing 
in athletes with T-wave inversion is one half that 
of comprehensive clinical evaluation (21% versus 
10%).
• The prevalence of cardiomyopathy in white ath-
letes with T-wave inversion is higher compared with 
black athletes with T-wave inversion (30% versus 
12%).
What Are the Clinical Implications?
• Genetic testing is rarely useful in the routine inves-
tigation of athletes with T-wave inversion who have 
undergone comprehensive clinical evaluation.
• In contrast, comprehensive clinical evaluation can 
identify a clinical diagnosis in more than one fifth 
of athletes with T-wave inversion on initial evalua-
tion, with a higher probability of a clinical diagno-
sis in white compared with black athletes (30.0% 
versus 12%).
• This study demonstrates that lateral T-wave inver-
sion in an athletic population referred to a spe-
cialized athletic center is associated with cardiac 
disease in 20% of athletes.
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recruited after direct referral to St. George’s Hospital for 
evaluation of TWI on clinical grounds from another institu-
tion or a professional sporting body in the United Kingdom. 
Exclusion criteria for recruitment into the study included car-
diac symptoms or a family history of cardiomyopathy or ion 
channel disease, a cardiac history, a medical history of hyper-
tension, use of anabolic steroids or performance-enhancing 
drugs, and a structurally abnormal heart or wall motion 
abnormalities on echocardiography.
Ethics Approval and Informed Consent
Ethics approval was obtained from the local ethics committee 
in accordance with the Declaration of Helsinki.17 Written con-
sent for enrollment of participants was obtained from indi-
viduals ≥16 years of age and from a parent or guardian for 
those <16 years of age. Genetic testing is not routinely per-
formed for the evaluation of athletes in the United Kingdom, 
and current European guidelines recommend disqualification 
of genotype-positive, phenotype-negative individuals from 
competitive sports.13 Therefore, the results of genetic testing 
were not given to the athlete or sports organization unless 
the athlete specifically requested the result after appropriate 
counseling and informed consideration of a positive test on 
the athlete’s career.
Clinical Investigations in Athletes
All athletes were also investigated with 12-lead ECG, signal-
averaged ECG, cardiopulmonary exercise stress testing, 24-hour 
ambulatory electrocardiographic monitoring, and CMR.
12-Lead ECG
Standard 12-lead ECG was performed with a MAC 5000 or 
MAC 5500 digital resting electrocardiographic recorder (GE 
Medical Systems, Milwaukee, WI) and analyzed as previously 
described.18 TWI of ≥−0.1 mV in ≥2 contiguous leads was 
considered significant, other than in leads V1, aVR, and III. The 
distribution of TWI was classified into 3 groups: TWI confined 
to the anterior leads (V1–V4); TWI involving the inferior leads 
(II, III, aVF), with or without anterior TWI; or TWI involving 
the lateral leads (I, aVL, V5, V6), regardless of TWI in the other 
leads.
Signal-Averaged ECG
Signal-averaged ECG was acquired according to accepted 
methodology19 with a MAC 5000 or MAC 5500 digital rest-
ing ECG recorder.
Cardiopulmonary Exercise Stress Testing
Cardiopulmonary exercise testing was performed in an 
upright position with a COSMED E100w cycle ergometer 
(Rome, Italy) as previously described20 using an incremental 
ramp protocol of 30 W/min in a quiet, air-conditioned room 
with an average temperature of 21°C and full resuscitation 
facilities. Subjects were encouraged to exercise to the point 
of exhaustion. Breath-by-breath gas exchange analysis was 
performed with a dedicated COSMED Quark CPEX metabolic 
cart. Blood pressure was measured before the test and then 
at 3-minute intervals with an automated cuff. Signals from 
a 12-lead ECG were displayed continuously and recorded at 
2-minute intervals with a COSMED Quark C12x electrocardio-
graphic recorder.
24-Hour Ambulatory Electrocardiographic 
Monitoring
Twenty-four-hour ambulatory electrocardiographic monitor-
ing (Lifecard CF Holters, Spacelabs Healthcare, Snoqualmie, 
WA) was performed specifically to detect supraventricular 
and ventricular arrhythmias.21 Nonsustained ventricular tachy-
cardia was defined as ≥3 consecutive ventricular beats at a 
rate of >120 bpm with a duration of <30 seconds.
Cardiac Magnetic Resonance Imaging
CMR was performed with previously described methods and 
analyzed with semiautomated software.7 All volumes and 
masses were indexed for age and body surface area according 
to the Du Bois and Du Bois22 formula. Late gadolinium images 
were acquired after intravenous gadolinium-DTPA administra-
tion.7 The presence or absence of late gadolinium enhance-
ment (LGE) was recorded as a binary variable.
Candidate Disease and Gene Selection 
for Genetic Testing
Genetic testing was performed for priority genes respon-
sible for 6 inherited cardiac conditions most commonly 
associated with TWI, namely hypertrophic cardiomyopathy 
(HCM),23 arrhythmogenic right ventricular cardiomyopa-
thy,24 dilated cardiomyopathy,25 left ventricular (LV) non-
compaction (LVNC),26 long-QT syndrome (LQTS),27,28 and 
Brugada syndrome.29 To ensure that comprehensive genetic 
evaluation was performed, a large number of potential can-
didate genes were also tested after a systematic literature 
review. Overall, a total of 104 genes for HCM (including 
phenocopies), 21 genes for arrhythmogenic right ventricu-
lar cardiomyopathy, 96 genes for dilated cardiomyopathy, 
37 genes for LVNC, 28 genes for LQTS, and 25 genes for 
Brugada syndrome were tested (Table I in the online-only 
Data Supplement).
Definitions of Clinical Diagnoses
The diagnosis of a cardiomyopathy (HCM, arrhythmogenic 
right ventricular cardiomyopathy, dilated cardiomyopathy, 
and LVNC) or an ion channel disorder (LQTS and Brugada 
syndrome) was made in accordance with internationally rec-
ognized guidelines.23,29–31 In particular, the diagnosis of HCM 
was based on LV hypertrophy (LVH) ≥15 mm in any myocar-
dial segment, as assessed on CMR, in the absence of another 
cardiac disorder or systemic condition capable of producing 
the same magnitude of LVH.32,33 In cases of mild LVH, HCM 
was diagnosed in the context of a combination of features, 
including nonconcentric patterns of LVH; LGE on CMR; an 
established or likely pathogenic gene mutation; the pres-
ence of broader phenotypic features of the condition such 
as nonsustained ventricular tachycardia or a blunted blood 
pressure response to exercise; and, in the case of apical HCM, 
the appearance of relative apical hypertrophy and cavity oblit-
eration out of keeping with athletic training in combination 
with typical lateral deep TWI.34–36 Phenocopies of HCM were 
diagnosed on the basis of the above criteria and confirmation 
by a relevant pathogenic genetic test. The diagnosis of LVNC 
was based on increased trabeculation of the LV myocardium 
fulfilling recognized CMR criteria37 and the concurrent pres-
ence of wall thinning or LV systolic dysfunction.
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Genetic Testing in Athletes
Sample Preparation, Genetic Sequencing, and 
Analysis
Genomic DNA was extracted from 1 mL peripheral blood 
samples. Sequencing of all coding exons and intronic 
flanking regions was performed through massive parallel 
sequencing technology. Targeted enrichment of the genes 
associated with each condition was performed. Sample 
preparation was conducted with the SureSelect Target 
Enrichment Kit (Agilent, California, Santa Clara, CA) for 
Illumina (San Diego, CA) paired-end multiplexed sequencing 
method, following the manufacturer’s instructions. Regions 
of interest were captured with a custom probe library. 
Sequencing was performed on an Illumina HiSeq 1500 
with 2×100 base read length following Illumina protocols. 
Low-coverage regions (defined as every base with depth of 
coverage <15×) in those genes related to the diseases in 
question were resequenced through the Sanger method. 
Bioinformatic analysis was performed by means of a cus-
tom pipeline that included Novoalign (Novocraft, Selangor, 
Malaysia), Samtools (Genome Research Ltd, Wellcome Trust 
Sanger Institute, Hinxton, UK), Genome Analysis Toolkit 
(Broad Institute, Cambridge, MA), and bcftools (Genome 
Research Ltd) for variant calling and genotyping and Annovar 
for variant annotation.
Determination of Variant Frequency
Information on the frequency of identified genetic vari-
ants in different populations was analyzed from (1) the 
Exome Variant Server, National Heart, Lung, and Blood 
Institute GO Exome Sequencing Project, Seattle, WA (http://
evs.gs.washington.edu/EVS/); (2) the 1000 Genomes 
Project (www.1000genomes.org/); (3) the Database of 
Single Nucleotide Polymorphisms, National Center for 
Biotechnology Information, US National Library of Medicine, 
Bethesda, MD (https://www.ncbi.nlm.nih.gov/snp/); (4) the 
Human Gene Mutation Database38 (www.hgmd.cf.ac.uk); 
(5) ClinVar39; and (6) the Exome Aggregation Consortium, 
Cambridge, MA, and the Genome Aggregation Database 
(http://exac.broadinstitute.org, and http://gnomad.broadin-
stitute.org).
Definitions and Pathogenicity of Identified 
Variants
Identified variants were classified as mutations if absent in 
control populations, rare variants if present in <1% of control 
populations, and polymorphisms if present in ≥1% of con-
trol populations. The pathogenicity of the identified variants 
was classified according to current recommendations from 
the American College of Medical Genetics and Genomics.40 
In summary, variants were considered potentially pathogenic 
if they were absent or rare in healthy control subjects, previ-
ously associated with disease development, and functionally 
relevant variants in genes previously associated with the iden-
tified phenotype (eg, in-frame or frameshift-causing inser-
tions or deletions, variants affecting splice sites, or missense 
variants likely to be pathogenic as identified by software 
models such as SIFT,41 PolyPhen,42 and MutationTaster243). A 
detailed description of the methods used to determine patho-
genicity of identified variants is summarized in Table II in the 
online-only Data Supplement.
Statistical Analysis
The Kolmogorov-Smirnov test was used to evaluate whether 
each continuous parameter followed a gaussian distribu-
tion. Values are expressed as absolute numbers and percent-
ages for categorical data and mean±SD for continuous data. 
Comparisons were performed with the χ2 test or Fisher exact 
test for categorical variables, unpaired t test for normally 
distributed continuous variables, and Mann-Whitney U test 
for nonnormally distributed continuous variables. A 2-tailed 
value of P<0.05 was considered significant throughout. All 
analyses were performed with SPSS software, version 20.0 
(IBM Analytics).
RESULTS
Athlete Demographics
There were no differences between black and white 
athletes with respect to age, sex, body surface area, 
resting blood pressure, and hours of exercise per week 
(Table 1). All athletes had a resting blood pressure of 
<140/90 mm Hg. The majority of athletes (≥90%) in 
both groups were men.
Electrocardiographic Characteristics
All athletes were in sinus rhythm. TWI extending into 
the lateral leads was the most common pattern of TWI 
in both black and white athletes, followed by TWI con-
fined to the anterior leads V1 through V4 (Table 2). Of 
note, there was a relatively high prevalence of path-
ological Q waves and ST-segment depression in both 
groups; ST-segment depression was observed in at least 
one fifth (Table 2). Most athletes revealed 1 abnormal 
parameter on signal-averaged ECG, and 7 black (14%) 
and 6 white (12%) athletes revealed ≥2 abnormal pa-
rameters.
Structural Characteristics on CMR
Consistent with previous studies, white athletes had 
greater LV and right ventricular volumes on CMR com-
pared with black athletes, whereas black athletes had a 
Table 1. Demographic Characteristics of Black and White Athletes
 
Black 
Athletes
(n=50)
White 
Athletes
(n=50)
P 
Value
Age, y 22.7±7.3 25.1±7.1 0.065
Male sex, n (%) 49 (98) 45 (90) 0.092
Body surface area, m2 1.97±0.26 2.00±0.22 0.321
Systolic blood pressure at rest, mm Hg 124.1±11.3 122.1±11.6 0.393
Diastolic blood pressure at rest, mm Hg 75.1±10.2 76.0±11.8 0.336
Amount of exercise per week, h 13.4±4.4 13.4±5.5 0.961
Data are shown as absolute and relative (percent) number of subjects for 
categorical variables and as mean±SD for continuous parameters. 
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greater mean maximal LV wall thickness (Table 2). Five 
black athletes (10%) and 5 white athletes (10%) re-
vealed LGE.
Cardiopulmonary Exercise Testing and 
Holter Monitoring
Three athletes with HCM demonstrated an abnormal 
blood pressure response to exercise. Two athletes with 
HCM had a short run of nonsustained ventricular tachy-
cardia. One athlete without a diagnosis of cardiomy-
opathy demonstrated transient asymptomatic atrioven-
tricular reentrant tachycardia.
Diagnoses Based on Clinical 
Investigations
In total, 21 athletes (21%) were diagnosed with car-
diac disease on the basis of comprehensive clinical in-
vestigation. HCM was the most common diagnosis and 
affected 19 of the 21 athletes (90.5%). The diagnosis 
of HCM was based predominately on the degree and 
segmental nature of LVH on CMR and LGE. One ath-
lete (4.8%) with extracardiac features was diagnosed 
with Fabry disease (later confirmed on genetic testing), 
and 1 athlete (4.8%) was diagnosed with LVNC. A clini-
cal diagnosis of cardiomyopathy was more common in 
white athletes compared with black athletes (30% ver-
sus 12%; P=0.027). One black athlete (2%) revealed 
LGE on CMR in the absence of a clear diagnosis.
Diagnostic Yield of Genetic Testing
A genetic variant was identified in 63 athletes (63%); 
however, only 10 athletes revealed a disease-causing 
variant (pathogenic mutation [n=4] or variant of likely 
pathogenicity [n=6]), including 7 (14%) white athletes 
and 3 (6%) black athletes (Figure 1 and Table 3). The 
remaining 53 athletes were considered to have variants 
of unknown significance.
Of the 21 athletes with a clinical diagnosis, 8 indi-
viduals (38.1%; 6 white and 2 black) had a positive 
gene test consistent with the diagnosis (Figure 1 and 
Table 3). Of these 8 athletes, 6 athletes (5 white and 
1 black) were diagnosed with HCM; 1 white athlete 
was diagnosed with Fabry disease; and 1 black athlete 
was diagnosed with LVNC (Figure 1 and Table III in the 
online-only Data Supplement).
Among the remaining 79 athletes without a clinical 
diagnosis, 2 (2.5%) were identified with a disease-
causing variant in the absence of a clinical phenotype. 
Specifically, 1 white athlete had a likely pathogenic 
rare variant in the sodium voltage-gated channel al-
pha subunit 5 (SCN5A) gene previously reported to 
be associated with LQTS, and 1 black athlete had a 
pathogenic polymorphism in the transthyretin (TTR) 
gene that is found in up to 4% of black individuals 
Table 2. Electrocardiographic and Cardiac Magnetic Resonance Imaging Characteristics of Black and White Athletes
 
Black Athletes
(n=50)
White Athletes
(n=50) P Value
12-Lead electrocardiogram, n (%)
  Left bundle-branch block 0 (0.0) 0 (0.0) …
  Pathological Q waves 2 (4.0) 3 (6.0) 0.646
  T-wave inversion 100 (100) 100 (100) …
   Confined to V1–V4 15 (30.0) 17 (34.0) 0.831
   Extending to inferior leads 3 (6.0) 8 (16.0) 0.200
   Extending to lateral leads 32 (64.0) 25 (50.0) 0.225
   Deep T-wave inversion 48 (96.0) 41 (82.0) 0.025
  ST-segment depression 10 (20.0) 11 (22.0) 0.806
Cardiac magnetic resonance imaging
  Maximum LV wall thickness, mm 11.9±2.1 11.3±2.4 0.232
  LV end-diastolic volume index, mL/m2 85.5±15.7 98.7±17.8 <0.001
  LV ejection fraction, % 66.7±9.7 69.0±8.7 0.251
  LV wall/LV end-diastolic volume index, mm·m2/mL 0.14±0.05 0.12±0.06 0.026
  LV mass index, g/m2 85.1±18.6 84.6±20.6 0.910
  Right ventricular end-diastolic volume index, mL/m2 84.9±13.5 100.3±20.9 0.001
  Right ventricular ejection fraction, % 61.5±9.0 65.2±9.0 0.100
  Late gadolinium enhancement, n (%) 5 (10.0) 5 (10.0) …
Data are shown as absolute and relative (percent) number of subjects for categorical variables and as mean±SD for continuous 
parameters. LV indicates left ventricular.
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and associated with the development of wild-type 
transthyretin amyloidosis.
Electric Changes in Athletes With a 
Cardiac Diagnosis
Pathological Q waves and ST-segment depression were 
more common in athletes with cardiac disease compared 
with those without cardiac disease (Table  4). Almost all 
athletes diagnosed with cardiac disease (n=20, 95.2%) re-
vealed TWI in the lateral leads (Figure 2). TWI limited to the 
anterior leads was detected in just 1 white athlete (4.8%) 
with cardiac pathology (Figure 2). The same athlete also re-
vealed coexisting pathological Q waves. None of the black 
athletes with anterior TWI was diagnosed with a cardiomy-
opathy or an ion channel disorder. One 23-year-old black 
athlete with anterior TWI harbored a pathogenic mutation 
in the TTR gene associated with wild-type transthyretin 
amyloidosis. None of the athletes with TWI confined to 
the inferior leads was diagnosed with cardiac disease or 
revealed a pathogenic genetic mutation.
Costs Per Diagnosis Associated With 
Clinical and Genetic Testing
The cost of clinical evaluation amounted to US$1084 
per athlete using standard National Health Service Tar-
iffs and an exchange rate of £1 to US$1.28. This figure 
equated to a cost of US$5162 per athlete diagnosed 
with cardiac disease. Addition of genetic testing in-
creased the cost of evaluation by 3-fold to US$3267 
per athlete, equating to a cost of US$14 204 per ath-
lete with a clinical or genetic diagnosis and a cost of 
US$32 670 per genetic diagnosis alone. The cost of 
making additional diagnoses beyond clinical evaluation 
based on genetic testing (2 genotype-positive individu-
als without a clear clinical phenotype) was US$109 150 
per athlete.
DISCUSSION
The present study investigated whether genetic testing 
for mutations capable of causing cardiomyopathy and 
ion channel diseases has a potential role in determining 
the clinical significance of TWI in both black and white 
athletes over and above standard clinical evaluation.18 
The cohort of athletes is unique, and recruitment was 
possible only through the assessment of a large num-
ber of athletes from several different referral sources. 
Although a total of 2039 athletes were evaluated in 
our own sports cardiology clinic over the 2-year study 
period, these individuals were referred from a pool of 
>5400 athletes assessed by CRY and >3000 athletes 
Figure 1. Breakdown of athletes with clinical and genetic diagnoses. 
The diagnostic yield with comprehensive clinical investigation was 21% compared with 10% using genetic testing. Of the 21 athletes diagnosed with cardiac dis-
ease on the basis of clinical investigation, 8 (38.1%) were gene positive (myosin binding protein C [MYBPC3], myosin heavy chain 7 [MYH7], galactosidase alpha 
[GLA], and actin, alpha, cardiac muscle 1 [ACTC1] genes) and 13 (61.9%) were gene negative. Of the remaining 79 athletes without a clinical diagnosis, 2 (2.5%) 
were gene positive (transthyretin [TTR] and sodium voltage-gated channel alpha subunit 5 [SCN5A] genes) in the absence of a clinical phenotype. HCM indicates 
hypertrophic cardiomyopathy; LQTS, long-QT syndrome; and LVNC, left ventricular noncompaction.
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assessed by Qatar Orthopaedic and Sports Medicine 
Unit during the same study period. A significant pro-
portion of athletes were also referred to us after being 
assessed at different institutions throughout the United 
Kingdom. Although it is more challenging to provide 
the precise denominator for this referral group, the ma-
jority of athletes in the present study (57%) revealed 
lateral TWI. On the basis of our own screening experi-
ence that only 4% of black3,5 and 0.3% of white2,3,5 
athletes in the United Kingdom reveal lateral TWI, we 
estimate that the total number of athletes required 
to derive a cohort of athletes with the TWI patterns 
described in this study would exceed 11 000.
Diagnostic Yield From Genetic Testing
The overall diagnostic yield from genetic testing for a 
pathogenic or likely pathogenic mutation in athletes 
with TWI was 10% compared with 21% after compre-
hensive clinical evaluation. Genetic testing was positive 
in just 8 athletes (38.1%) with a clinical diagnosis of 
cardiomyopathy despite a very comprehensive panel of 
genes being tested. Of these, 6 athletes (75.0%) were 
white. Genetic testing identified an additional 2 ath-
letes (2.5%) with TWI but no clear clinical phenotype 
who harbored potential cardiac disease. Compared 
with a recent study by Kadota et al44 in which 5 of 102 
Japanese athletes (4.9%) with electrocardiographic 
abnormalities screened for mutations in 4 sarcomeric 
genes (myosin heavy chain 7 [MYH7], myosin binding 
protein C [MYBPC3], troponin T2, cardiac type [TNNT2], 
and troponin 13, cardiac type [TNNI3]) showed a posi-
tive result, our yield was significantly higher and likely 
reflects the comprehensive genetic panel used.
The yield for pathogenic mutations in our athletes 
clinically diagnosed with HCM was half that expected 
from the published literature (32% versus ≈60%–70%). 
One third of the athletes diagnosed with HCM exhib-
ited the apical variant, which has been shown to have a 
lower-than-usual genetic yield.45 The current false-neg-
ative rate of genetic testing in our cohort indicates that 
routine genetic testing in athletes with TWI who have 
undergone comprehensive clinical evaluation will sup-
port a possible diagnosis of cardiomyopathy in a few 
cases at a substantial cost. These observations do not 
support the routine use of genetic testing for the evalu-
ation of asymptomatic athletes with TWI in the absence 
of a family history of an inherited cardiac condition.
Table 3. Clinical Diagnoses Made in Athletes
Athlete Age, y Gene Mutation Pathogenic Clinical Diagnosis T-Wave Inversion Diagnosis Based on
White athletes
  15 34 MYBPC3 Yes Apical HCM A, I, L CMR and gene test
  21 34 No … Apical HCM A, I, L CMR
  25 35 No … Apical HCM A, L CMR
  27 35 No … Apical HCM A, L CMR
  31 20 No … HCM I, L CMR
  35 14 No … HCM I, L CMR
  47 35 No … HCM A, I, L CMR
  49 19 MYBPC3 Likely HCM A CMR
  53 33 No … HCM I, L CMR
  55 34 MYPBC3 Likely HCM A, I, L CMR
  60 24 MYH7 Likely HCM A, L CMR
  62 25 No … Apical HCM A, I, L CMR
  74 34 GLA Yes Fabry disease A, I, L CMR and gene test
  77 34 MYBPC3 Yes HCM A, L CMR and gene test
  123 18 No … HCM A, I, L CMR
Black athletes
  7 34 No … HCM A, L CMR
  3 17 MYH7 Likely Apical HCM A, I, L CMR and gene test
  57 17 No … Apical HCM A, I, L CMR
  86 25 No … HCM A, I, L CMR
  91 15 No … HCM A, L CMR
  92 13 ACTC1 Likely LVNC A, I, L CMR and gene test
A indicates anterior; ACTC1, actin alpha, cardiac muscle 1; CMR, cardiac magnetic resonance imaging; GLA, galactosidase alpha; HCM, hypertrophic 
cardiomyopathy; I, inferior; L, lateral; LVNC, left ventricular noncompaction; MYBPC3, myosin binding protein C; and MYH7, myosin heavy chain 7.
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Although genetic testing identified a potentially se-
rious SCN5A mutation implicated in LQTS in a white 
female athlete with TWI, she did not show any features 
of the disorder, including a prolonged corrected QT 
interval. Similarly, gene testing identified a definitive 
transthyretin mutation in a black athlete without 
Table 4. Electrical, Structural, and Functional Characteristics of Athletes Diagnosed With Structural Cardiac Disease Compared With 
Those Without Cardiac Disease
Parameter
Athletes With Structural 
Diagnosis (n=21)
Athletes Without Structural 
Diagnosis (n=79) P Value
12-Lead ECG, n (%)
  Pathological Q waves 4 (19.1) 1 (1.3) 0.001
  Deep T-wave inversion 21 (100) 68 (86.1) 0.070
  T-wave inversion confined to the anterior leads 1 (4.8) 31 (39.2) 0.003
  Lateral T-wave inversion 20 (95.2) 37 (46.8) <0.001
  ST-segment depression 10 (47.6) 11 (13.9) 0.001
  QRS fragmentation 2 (9.5) 16 (20.3) 0.255
Structural, cardiac magnetic resonance imaging
  LV end-diastolic volume index, mL/m2 86.0±14.2 92.0±18.0 0.135
  Right ventricular end-diastolic volume index, mL/m2 89.9±17.7 92.8±19.3 0.616
  Maximum LV wall thickness, mm 14.6±2.0 10.8±1.8 <0.001
  LV wall/LV end-diastolic volume index, mm·m2/mL 0.17±0.12 0.07±0.04 0.001
  LV mass index, g/m2 89.4±23.1 83.4±18.1 0.216
  Late gadolinium enhancement, n (%) 8 (38.1) 2 (2.5) <0.001
Cardiopulmonary exercise testing and 24-hr ambulatory electrocardiographic monitoring
  Peak oxygen uptake, mL·min−1·kg−1 42.6±7.2 43.7±7.3 0.563
  Predicted peak oxygen uptake, % 103.9±17.8 106.0±19.1 0.798
  Nonsustained ventricular tachycardia, n (%) 2 (9.5) 0 (0.0) 0.051
Data are shown as absolute and relative (percent) number of subjects for categorical variables and as mean±SD for continuous parameters. LV indicates 
left ventricular.
Figure 2. Comparison of clinical and genetic diagnoses in black and white athletes in relation to the distribution of T-wave inversion (TWI). 
ACTC1 indicates actin, alpha, cardiac muscle 1; GLA, galactosidase alpha; HCM, hypertrophic cardiomyopathy; LQTS, long-QT syndrome; LVNC, left ventricular 
noncompaction; MYBPC3, myosin binding protein C; MYH7, myosin heavy chain 7; SCN5A, sodium voltage-gated channel alpha subunit 5; and TTR, transthyretin.
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evidence of cardiac amyloidosis at this young age, and 
it is known that this variant is detected in up to 4% of 
the black population. These observations also highlight 
that routine gene testing without appropriate clinical 
indications may be confusing, cause unnecessary con-
cern, and be problematic for decision making.
Association Between Pattern of TWI and 
Cardiac Pathology
In both black and white athletes, TWI extending into 
the lateral leads was the most common pattern en-
countered (64% versus 50%, respectively; Figure  2). 
Although previous studies in both black and white ath-
letes report anterior TWI (V1–V4) to be the most com-
mon pattern observed,3 our cohort almost certainly re-
flects a referral bias in favor of individuals with lateral 
TWI in whom suspicion of a cardiomyopathy is higher. 
Furthermore, given that anterior TWI is now widely 
recognized as a normal, ethnicity-specific training vari-
ant in black athletes, referral bias may also explain the 
similar prevalence of anterior TWI observed in our black 
and white cohorts, with fewer black athletes exhibiting 
anterior TWI being referred for evaluation.
ST-segment depression was found exclusively in ath-
letes with lateral TWI, regardless of ethnicity. All but 1 
of our 21 athletes (95%) exhibiting structural disease 
revealed lateral TWI (Table 3 and Figure 2). Indeed, the 
diagnostic yield of lateral TWI for a clinical diagnosis of 
cardiomyopathy in black and white athletes was 18.8% 
and 56%, respectively. In comparison, the yield for mu-
tations associated with cardiomyopathy in athletes with 
lateral TWI was 12.3%.
Compared with white athletes, a smaller proportion 
of black athletes with TWI (n=6, 12%) were diagnosed 
with a cardiomyopathy (Table 3). Of these individuals, 
all exhibited TWI in the lateral leads, reinforcing the no-
tion that this particular repolarization pattern should be 
viewed with caution, even in the black athletic popula-
tion in whom its prevalence approaches 5%.3 Anterior 
TWI in black athletes was not associated with overt 
cardiomyopathy, ion channel disorders, or pathogenic 
genetic mutations, suggesting that this pattern is likely 
benign.46
Overall Number of Diagnoses Made and 
Yield From CMR
Significantly fewer black athletes were diagnosed with 
a cardiomyopathy compared with white athletes (12% 
versus 30%; P=0.027), suggesting that TWI may be 
more representative of subtle forms of cardiomyopa-
thy in white individuals. The only other study to com-
prehensively investigate athletes with TWI with CMR 
evaluated 155 athletes.4 The authors diagnosed 37 
athletes with a cardiomyopathy (predominantly HCM) 
on initial echocardiography. Of the remaining 118, 
a further 24 athletes (20.3%) were diagnosed with 
CMR, a figure comparable to the 21 athletes (21.0%) 
diagnosed in the present study, and a further 3 ath-
letes (2.5%) were diagnosed on the basis of Holter 
monitoring and exercise testing. In this study, Holter 
monitoring and exercise stress testing revealed the 
broader phenotypic features of HCM in over 26% of 
affected athletes.
Study Limitations
The present study has several limitations. Inherited car-
diomyopathies exhibit an age-related penetrance; thus, 
it is possible that cardiac disease was underdiagnosed in 
our cohort. Our population consisted of predominately 
young male athletes. Therefore, any conclusions about 
the significance of TWI in female or master athletes 
cannot be extrapolated from this study. It was also not 
possible to perform familial evaluation of first-degree 
family members, which would have been a valuable 
source of information to help determine the genetic 
significance of TWI in borderline cases, even in the ab-
sence of a pathogenic mutation. Cosegregation studies 
were not performed and would have been important to 
determine the pathogenicity of several of the identified 
variants. Finally, the absence of a pathogenic mutation 
does not exclude the possibility of underlying disease, 
and several athletes revealed variants of undetermined 
clinical significance; thus, long-term clinical follow-up 
is warranted.
Conclusions
Up to 10% of athletes with TWI show definitive or likely 
pathogenic mutations for cardiomyopathy or ion chan-
nel disease. Compared with standard clinical practice, 
the relatively low diagnostic yield and high cost of ge-
netic testing make it of negligible use in routine clinical 
practice. Although genetic testing may help identify indi-
vidual athletes with TWI and a potential cardiac disorder 
in the absence of a clear clinical phenotype, our results 
suggest that it is not indicated in the routine evaluation 
of asymptomatic athletes with TWI in the absence of a 
family history of an inherited cardiac condition.
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